Synthesis of mixed-valent {alpha}- and {beta}-NaFe{sub 2}O{sub 3} polymorphs under controlled partial oxygen pressure
- Department of Chemistry, Michigan State University, East Lansing, MI 48824 (United States)
Synthesis of mixed valent compounds, especially when multiple polymorphs exist, requires careful control of the preparation conditions. {alpha}- and {beta}-NaFe{sub 2}O{sub 3} polymorphs were synthesized under controlled partial oxygen pressure (pO{sub 2}). pO{sub 2} regions of stability at 850 Degree-Sign C were determined for both phases for the first time. A modified oxygen buffer method was developed for the facile preparation of mixed valent oxides under controlled pO{sub 2}. {beta}-NaFe{sub 2}O{sub 3} is the only known n=2 member of the AM{sub n}O{sub n+1} (A=alkali metal, M=3d metal) rock-salt related homolog series with layered cation ordering. The possibility of new members of the homolog series with other 3d metals is considered. - Graphical abstract: Schematic section of phase composition vs. partial O{sub 2} pressure diagram at 850 Degree-Sign C for Na/Fe=1/2 and structure models of {alpha}- and {beta}-NaFe{sub 2}O{sub 3}. Highlights: Black-Right-Pointing-Pointer {alpha}- and {beta}-NaFe{sub 2}O{sub 3} polymorphs were synthesized under controlled oxygen pressure. Black-Right-Pointing-Pointer {beta}-NaFe{sub 2}O{sub 3} has rock-salt related structure with layered cation ordering. Black-Right-Pointing-Pointer Existence of the rock-salt related homolog series AM{sub n}O{sub n+1} is discussed.
- OSTI ID:
- 22131102
- Journal Information:
- Journal of Solid State Chemistry, Vol. 192; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0022-4596
- Country of Publication:
- United States
- Language:
- English
Similar Records
Synthesis, structures and properties of the new lithium cobalt(II) phosphate Li{sub 4}Co(PO{sub 4}){sub 2}
Ionothermal synthesis of uranyl compounds that incorporate imidazole derivatives